| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 7.9K | 6.1% |
| Total Income | 8.0K | 6.4% |
| Expenditure | 6.8K | 5.3% |
| PBT | 1.2K | 11.9% |
| Net Profit | 824.20 | 8.7% |
| OPM | 20.37% | 1.01pp |
| NPM | 10.34% | 0.26pp |
| EPS | 14.20 | 8.7% |
Aurobindo Pharma Reports Q1FY26 Revenue Growth of 4.0% YoY to INR 7,868 Cr
04 Aug 2025 · 4 Aug 2025, 08:04 pm
Summary
Aurobindo Pharma Limited has reported its consolidated financial results for the quarter ended June 30, 2025. The company's revenue from operations increased by 4.0% YoY to INR 7,868 Cr with growth in Europe and a marginal decline in US formulations revenue. EBITDA before R&D stood at INR 1,947 crores with a margin of 24.8%. The company received final approval for 14 ANDAs from the USFDA and launched 15 products during the quarter.
Key Highlights
- 1
Revenue from Operations increased by 4.0% YoY to INR 7,868 Cr
- 2
US formulations revenue marginally declined by 1.9% YoY to INR 3,488 Cr
- 3
Europe formulations revenue increased by 18.0% YoY to INR 2,338 Cr
- 4
Growth Markets revenue increased by 8.8% YoY to INR 772 Cr
- 5
ARV revenue increased by 55.2% YoY to INR 355 Cr
- 6
APl revenue decreased by 16.% YoY to INR 916 Cr
- 7
Received final approval for 14 ANDAs from the USFDA
- 8
Launched 15 products during the quarter
Management Comments
Mr. K. Nithyananda Reddy
We started the year steadily, with our European business maintaining strong growth momentum and our core US business showing resilience despite temporary challenges from destocking and seasonal dynamics. Our disciplined execution, operational initiatives, and recent US acquisition strengthens our commercial footprint and accelerates growth potential.
Informational and educational content only. Not investment advice.